'Mounjaro,' Obesity Treatment, to Launch 15mg High-Dose Version in Korea Tomorrow
Supply of 12.5mg and 15mg Versions
High-dose versions of Mounjaro (active ingredient: tirzepatide), a treatment for diabetes and obesity, are set to launch in Korea.
According to the pharmaceutical industry on June 9, single-use prefilled pen versions of Mounjaro in 12.5mg and 15mg doses will be supplied in Korea starting the following day. Previously available doses included 2.5mg, 5mg, 7.5mg, and 10mg.
Eli Lilly's diabetes treatment Mounjaro (active ingredient tirzepatide). Eli Lilly
View original imageMounjaro has been approved in Korea as an adjunct to diet and exercise for improving blood sugar control in patients with type 2 diabetes, managing weight in patients who are obese or overweight, and treating obstructive sleep apnea.
The company stated that in a clinical study involving adults with obesity, after 72 weeks, the average weight loss was 16% in the 5mg group, 21.4% in the 10mg group, and 22.5% in the 15mg group.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Eli Lilly Korea believes the launch of these higher-dose products will offer new hope for patients who have struggled to achieve their treatment goals with the previously available dosages.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.